3 citations
,
June 2025 in “Archives of Dermatological Research” Biologics and JAK inhibitors may improve treatment for scarring alopecias.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
21 citations
,
May 2024 in “Journal of Ethnopharmacology”
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” 2 citations
,
February 2024 in “Indian Dermatology Online Journal” Tofacitinib effectively improved hair regrowth and skin condition in a woman with alopecia totalis and lichen planus hypertrophicus.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
10 citations
,
August 2016 in “Oxford Medical Case Reports” Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
2 citations
,
January 2004 in “Linchuang pifuke zazhi” ZD1839 can cause skin issues like acne and hair changes.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.